Profile data is unavailable for this security.
About the company
Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
- Revenue in EUR (TTM)504.86m
- Net income in EUR19.37m
- Incorporated1967
- Employees2.74k
- LocationBoiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
- Phone+33 478456100
- Fax+33 478456291
- Websitehttps://www.boiron.fr/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Kawin Technol Sha-hld Co Ltd | 141.51m | 16.89m | 465.85m | 600.00 | 27.98 | 2.06 | -- | 3.29 | 0.789 | 0.789 | 6.61 | 10.73 | 0.4166 | 1.52 | 2.64 | 1,910,937.00 | 5.26 | 5.55 | 7.12 | 7.14 | 81.89 | 84.98 | 12.64 | 9.40 | 2.55 | -- | 0.2017 | 45.97 | -12.87 | 8.32 | 22.18 | 21.60 | 40.30 | -- |
| Zhejiang Cheng Yi Pharmaceutical Co Ltd | 97.61m | 27.94m | 470.21m | 738.00 | 16.64 | 2.88 | -- | 4.82 | 0.6997 | 0.6997 | 2.46 | 4.04 | 0.4508 | 1.95 | 20.88 | -- | 13.02 | 11.48 | 15.87 | 14.03 | 68.99 | 69.02 | 28.88 | 24.63 | 0.985 | -- | 0.0808 | 37.22 | 6.36 | 0.9546 | 23.21 | 8.84 | -20.09 | 11.39 |
| Ironwood Pharmaceuticals, Inc. | 250.68m | 20.33m | 472.03m | 100.00 | 31.72 | -- | 21.53 | 1.88 | 0.1078 | 0.1078 | 1.86 | -1.61 | 0.792 | -- | 4.60 | 2,961,510.00 | 6.42 | -8.59 | 10.29 | -10.50 | -- | -- | 8.11 | -15.83 | -- | 4.14 | 1.81 | -- | -15.72 | -5.33 | 2,629.21 | -25.72 | -55.00 | -- |
| Nxera Pharma Co Ltd | 160.63m | -67.96m | 474.17m | 374.00 | -- | 1.43 | -- | 2.95 | -138.60 | -138.60 | 328.05 | 674.04 | 0.2069 | 0.8144 | 4.11 | -- | -8.75 | -3.79 | -9.90 | -4.16 | 72.32 | 80.12 | -42.31 | -22.17 | 1.90 | -1.30 | 0.4847 | -- | 2.71 | 27.35 | -158.99 | -- | 42.87 | -- |
| CorMedix Inc | 181.40m | 137.55m | 475.51m | 64.00 | 3.47 | 1.49 | 3.37 | 2.62 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Boiron SA | 504.86m | 19.37m | 480.74m | 2.74k | 24.56 | 1.29 | 7.84 | 0.9522 | 1.12 | 1.12 | 29.08 | 21.26 | 0.9021 | 1.30 | 6.51 | 182,193.40 | 3.46 | 4.01 | 4.34 | 5.04 | 73.71 | 73.23 | 3.84 | 5.81 | 1.46 | -- | 0.0467 | 66.42 | -1.15 | -2.63 | -68.36 | -22.53 | -15.75 | 2.71 |
| JCR Pharmaceuticals Co Ltd | 203.65m | -13.23m | 488.18m | 987.00 | -- | 1.83 | 193.55 | 2.40 | -19.98 | -19.98 | 307.86 | 379.76 | 0.3432 | 0.4534 | 2.50 | 38,039,510.00 | -2.21 | 5.86 | -3.77 | 9.33 | 70.45 | 73.83 | -6.45 | 13.60 | 0.668 | -- | 0.5295 | 45.13 | -22.86 | 5.94 | -186.42 | -- | 15.37 | 20.11 |
| Supriya Lifescience Ltd | 68.35m | 17.22m | 489.94m | 515.00 | 28.42 | -- | 24.95 | 7.17 | 23.05 | 23.05 | 91.47 | -- | -- | -- | -- | 14,280,700.00 | -- | 18.45 | -- | 21.63 | 72.33 | 59.62 | 25.19 | 25.45 | -- | 129.43 | -- | 3.59 | 22.11 | 17.45 | 57.80 | 20.69 | 45.94 | -- |
| Shanghai Shen Lian Biomedical Corp | 36.14m | -3.74m | 491.62m | 391.00 | -- | 2.83 | -- | 13.60 | -0.0739 | -0.0739 | 0.713 | 3.43 | 0.1864 | 1.42 | 0.9144 | 748,865.90 | -2.21 | 3.53 | -2.40 | 3.80 | 57.36 | 73.49 | -11.87 | 16.93 | 3.64 | -- | 0.0106 | 43.52 | 0.6394 | 3.63 | -241.95 | -- | -3.99 | -- |
Data as of Mar 02 2026. Currency figures normalised to Boiron SA's reporting currency: Euro EUR
5.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 30 Jun 2025 | 182.45k | 1.04% |
| Financi�re de l'�chiquier SAas of 30 Sep 2025 | 134.96k | 0.77% |
| Gay-Lussac Gestion SAas of 31 Dec 2024 | 106.00k | 0.60% |
| HMG Finance SAas of 31 Dec 2025 | 100.05k | 0.57% |
| HC Capital Advisors GmbHas of 31 Oct 2025 | 89.26k | 0.51% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 78.53k | 0.45% |
| DNCA Finance SAas of 31 Mar 2025 | 75.05k | 0.43% |
| Amiral Gestion SAas of 30 Jun 2025 | 62.05k | 0.35% |
| Sycomore Asset Management SAas of 30 Jan 2026 | 30.12k | 0.17% |
| Chaussier Gestion SAas of 31 Dec 2025 | 19.00k | 0.11% |
More ▼
Data from 31 Dec 2024 - 31 Jan 2026Source: FactSet Research Systems Inc.
